company background image
ARTV logo

Artiva Biotherapeutics NasdaqGM:ARTV Stock Report

Last Price

US$11.81

Market Cap

US$272.0m

7D

14.5%

1Y

n/a

Updated

25 Nov, 2024

Data

Company Financials +

Artiva Biotherapeutics, Inc.

NasdaqGM:ARTV Stock Report

Market Cap: US$272.0m

Artiva Biotherapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Artiva Biotherapeutics
Historical stock prices
Current Share PriceUS$11.81
52 Week HighUS$17.31
52 Week LowUS$9.68
Beta0
11 Month Change12.91%
3 Month Change10.58%
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-1.58%

Recent News & Updates

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Jul 22

Recent updates

Artiva: Natural Killer Cell Biotech With 1st Half Of 2025 Lupus Treatment Data

Jul 22

Shareholder Returns

ARTVUS BiotechsUS Market
7D14.5%4.0%2.2%
1Yn/a18.3%32.6%

Return vs Industry: Insufficient data to determine how ARTV performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ARTV performed against the US Market.

Price Volatility

Is ARTV's price volatile compared to industry and market?
ARTV volatility
ARTV Average Weekly Movement15.1%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ARTV's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ARTV's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201982Fred Aslanwww.artivabio.com

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate.

Artiva Biotherapeutics, Inc. Fundamentals Summary

How do Artiva Biotherapeutics's earnings and revenue compare to its market cap?
ARTV fundamental statistics
Market capUS$272.04m
Earnings (TTM)-US$61.28m
Revenue (TTM)US$2.60m

110.3x

P/S Ratio

-4.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARTV income statement (TTM)
RevenueUS$2.60m
Cost of RevenueUS$0
Gross ProfitUS$2.60m
Other ExpensesUS$63.88m
Earnings-US$61.28m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.52
Gross Margin100.00%
Net Profit Margin-2,355.86%
Debt/Equity Ratio0%

How did ARTV perform over the long term?

See historical performance and comparison